| Title： | Chinese expert consensus on the use of biologics in systemic lupus erythematosus |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | 各级临床医生（风湿病和其他相关领域） |
| Evidence classification method： | Grading of recommendations assessment, development and evaluation system |
| Development unit： | Chinese Primary Health Care Foundation, Chinese Rheumatology Association |
| Registration time: | 2023-07-24 |
| Registration number： | PREPARE-2023CN532 |
| Purpose of the guideline: | This expert consensus focused on the biologics used in systemic lupus erythematosus (SLE) in China. Based on clinical evidence, current guidelines and experts' opinion, this consensus provided physicians with up-to-date guidance on the appropriate use of biologics in the management of SLE, with detailed information in how to choose the target population for biologics, the timing of using biologics as well as the assessment of the efficacy and safety. Our objective was to promote the standardised use of biologics in the management of SLE. |
CURRENT Guidelines INFORMATION
Uploader：CNpubs@costellomedical,com
Upload Date：2023-07-24
Latest registration
